Advertisement

Topics

FDA Approves Kanjinti (trastuzumab-anns), a Biosimilar to Herceptin

21:06 EDT 12 Jun 2019 | Drugs.com

THOUSAND OAKS, Calif., June 13, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Kanjinti (trastuzumab-anns) for all approved indications of the...

Original Article: FDA Approves Kanjinti (trastuzumab-anns), a Biosimilar to Herceptin

NEXT ARTICLE

More From BioPortfolio on "FDA Approves Kanjinti (trastuzumab-anns), a Biosimilar to Herceptin"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...